Date: 17 Sep 2012
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Moxonidine (Physiotens®, Moxon®, Cynt®) is an orally administered imidazoline compound with selective agonist activity at imidazoline I1 receptors and only minor activity at α2-adrenoceptors. Moxonidine acts centrally to reduce peripheral sympathetic activity, thus decreasing peripheral vascular resistance. In patients with mild to moderate hypertension, moxonidine reduces blood pressure (BP) as effectively as most first-line antihypertensives when used as monotherapy and is also an effective adjunctive therapy in combination with other antihypertensive agents. It improves the metabolic profile in patients with hypertension and diabetes mellitus or impaired glucose tolerance, is well tolerated, has a low potential for drug interactions and may be administered once daily in most patients. Thus, moxonidine is a good option in the treatment of patients with mild to moderate hypertension, particularly as adjunctive therapy in patients with the metabolic syndrome.
Moxonidine is a centrally acting selective agonist at imidazoline I1 receptors, tor which it has an affinity >30-fold that for α2-adrenoceptors. Moxonidine inhibits peripheral sympathetic activity, which decreases peripheral vascular resistance and results in significant decreases in systolic and diastolic BP (SBP and DBP). Moxonidine has minimal effect on cardiac haemodynamics and reduces left ventricular mass. Markers of endothelial dysfunction and end-organ damage, including microalbuminuria, improved in hypertensive patients who achieved BP control with moxonidine. Moxonidine also improved the metabolic profile of patients with hypertension and type 2 diabetes or impaired glucose tolerance. Oral moxonidine is rapidly absorbed, although the maximum antihypertensive effect occurs 3–4 hours after administration.
Oral bioavailability is 88% and is unaffected by food. No first-pass metabolism occurs and moxonidine is mostly excreted unchanged in the urine.
In well designed, 8-week trials, monotherapy with moxonidine 0.2–0.6 mg/day reduced sitting DBP to a significantly greater extent than placebo (mean change from baseline −10.7 to −13.2 vs −2.3 to −9mm Hg) in patients with mild to moderate essential hypertension. Sitting SBP also improved from baseline to a significantly greater extent with moxonidine than with placebo (mean −19.5 to −24.9 vs −1.2 to −13mm Hg). Reductions in sitting SBP and DBP with moxonidine 0.2–0.8 mg/day at 8 weeks were similar to those with enalapril 5–20mg once daily, atenolol 50–100 mg/day (except in postmenopausal women where atenolol reduced BP to a greater extent than moxonidine), hydrochlorothiazide 25mg once daily and rilmenidine 1–2 mg/day. At 26 weeks, reductions in sitting SBP and DBP with moxonidine 0.2–0.4 mg/day were similar to those with nifedipine sustained release 20–40 mg/day.
Once-daily adjunctive moxonidine 0.4mg was also effective in patients with mild to moderate hypertension in well designed trials. In patients who did not respond to moxonidine monotherapy, mean improvements in sitting DBP at 4 weeks were −7.3mm Hg with moxonidine 0.4mg once daily plus amlodipine 5mg once daily, −4.8mm Hg with moxonidine 0.4mg once daily plus enalapril 10mg once daily and −3.2mm Hg with moxonidine 0.4mg once daily plus hydrochlorothiazide 12.5mg once daily. In another trial, changes in sitting SBP and DBP after 8 weeks’ treatment were significantly greater with once-daily moxonidine 0.4mg plus hydrochlorothiazide 25mg than with the respective monotherapies (−27 vs −20 and −22mm Hg and −16 vs −12 and −13mm Hg).
Moxonidine was generally well tolerated in clinical trials in patients with mild to moderate hypertension. In placebo-controlled monotherapy trials, 36–43% of moxonidine recipients experienced treatment-emergent adverse events versus 22–29% of placebo recipients and ≈32% and 35% of enalapril and hydrochlorothiazide recipients, respectively. Dry mouth was the most common adverse event with moxonidine monotherapy, affecting 11–20% of patients; other all-cause adverse events included diarrhoea, headache, bronchitis, nausea, dizziness and back pain. Other than dry mouth, asthenia and fatigue, adverse events in moxonidine monotherapy recipients were not generally related to α2-adrenoceptor inhibition. No new adverse events were reported in combination therapy trials.
Moxonidine was also well tolerated in a pooled analysis of postmarketing surveillance studies in 91 170 patients, about two-thirds of whom received moxonidine as monotherapy. Adverse events affected 9.4% of patients, causing 1.8% to discontinue treatment, and were generally not related to dosage, treatment duration, sex or age; dry mouth affected 4.2% of patients aged >65 years versus 2.7% of those aged <40 years.
Various sections of the manuscript reviewed by: Y. Ahmedani, Baqai Institute of Diabetes and Endocrinology, Baqai Medical University, Karachi, Pakistan; V.G. Athyros, Atherosclerosis and Metabolic Syndrome Units, Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece; A. Basit, Baqai Institute of Diabetes and Endocrinology, Baqai Medical University, Karachi, Pakistan; A. Fawwad, Baqai Institute of Diabetes and Endocrinology, Baqai Medical University, Karachi, Pakistan; M.M. Hoven, Department of General Internal Medicine, Leiden University Medical Centre, Leiden, The Netherlands; R. Padwal, Division of Internal Medicine, University of Alberta Hospital, Edmonton, Canada; B. Roca, Department of Medicine, General Hospital of Castellon, Castellon, Spain; A. Whaley-Connell, Department of Internal Medicine, Division of Nephrology, University of Missouri School of Medicine, Columbia, Missouri, USA.
Sources: Medical literature published in any language since 1980 on ‘moxonidine’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.
Search strategy: MEDLINE search terms were ‘moxonidine’ and ‘hypertension’ or ‘antihypertensive’. EMBASE search terms were ‘moxonidine’ and ‘hypertension’. AdisBase search terms were ‘moxonidine’ and ‘hypertension’ or ‘antihypertensive’. Searches were last updated 22 February 2006.
Selection: Studies in patients with essential hypertension who received moxonidine. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.
Index terms: Moxonidine, hypertension, imidazoline I1 receptor, metabolic syndrome, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability.
ESH-ESC Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 Jun; 21(6): 1011–53CrossRef
Brookes L. New definition of hypertension proposed [online]. Available from URL: http://www.medscape.com [Accessed 2005 Jun 9]
Prichard BNC, Owens CWI, Graham BR. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent. J Hum Hypertens 1997 Aug; 11 Suppl. 1: 29–45
Schaefer HG, Toublanc N, Weimann H-J. The pharmacokinetics of moxonidine. Rev Contemp Pharmacother 1998; 9(7): 481–90
Prichard BNC, Graham BR. The use of moxonidine in the treatment of hypertension. J Hypertens 1997 Jan; 15 Suppl. 1: 47–55
Schafers RF, Holzgreve H, Distler A, et al. Double blind, multicentre comparison of moxonidine and enalapril and their effects on blood pressure and left ventricular mass: results of the MOXENA study [abstract no. P1051]. J Hypertens 2002 Jun; 20 Suppl. 4: 249
Waters J, Ashford J, Jäger B, et al. Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension: results of the TOPIC (Trial Of Physiotens In Combination) study. J Clin Basic Cardiol 1999; 2(2): 219–24
Kirch W, Hutt HJ, Plänitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients. J Clin Pharmacol 1990 Dec; 30(12): 1088–95PubMed
Doumas MN, Douma SN, Petidis KM, et al. Different effects of losartan and moxonidine on endothelial function during sympathetic activation in essential hypertension. J Clin Hypertens (Greenwich) 2004 Dec; 6(12): 682–9CrossRef
Farsang C, Finta E, Kerkovits L, et al. Moxonidine possibly inhibits angiotensin converting enzyme inhibitor (ACEi)-induced cough in patients with essential hypertension: a multi-centre, open pilot study [abstract no. P2.216]. J Hypertens 2003 Jun; 21 Suppl. 4: 183
Troussov V, Acsenov C. Moxonidine (Phisiotens) in treatment of hypertension in elderly patients with type 2 diabetes mellitus [abstract no. 2543]. Diabetes Metab 2003 Aug; 29 (4 Suppl.): 314
Aparina T, Britov A, Gomazkov O. Effects of enalapril and moxonidine on left ventricular hypertrophy in relation to insulin resistance in hypertensive patients [abstract no. P1.198]. J Hypertens 2003 Jun; 21 Suppl. 4: 75
Reznik L, Koval S, Koval D, et al. The effects of moxonidine long-term monotherapy on endothelial vasoactive factors in patients with hypertension [abstract no. 99]. J Hypertens 2003 Jun; 21 Suppl. 4: 336
Sanjuliani AF, Genelhu de Abreu V, Ueleres Braga J, et al. Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma renin activity, plasma aldosterone, leptin, and metabolic profile in obese hypertensive patients. J Clin Basic Cardiol 2004; 7: 19–25
Orynchak MA, Neyko EM, Chovganyuk OS. Role of moxonidine in insulin secretion and endothelial dysfunction in the patients with insulin resistance [abstract no. P-538]. Am J Hypertens 2005 May 2; 18(5): 202–3
Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Hannover: Solvay Pharmaceuticals, 2005. (Data on file)
Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens Suppl 1999; 17 Suppl. 3: S29–35
Kaaja R, Manhem K, Tuomilehto J. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist. Int J Clin Pract 2004 Mar; Suppl. 139: 26–32
Jacob S, Klimm HJ, Rett K, et al. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004 Jun; 112(6): 315–22
Strojek K, Grzeszczak W, Górska J, et al. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001 Mar; 12: 602–5PubMed
El-Ayoubi R, Menaouar A, Gutkowska J, et al. Urinary responses to acute moxonidine are inhibited by natriuretic peptide receptor antagonist. Br J Pharmacol 2005 May; 45(1): 50–6CrossRef
Solvay Healthcare Limited. Physiotens tablets 200, 300 & 400 micrograms: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2005 Jun 13]
Sleight P. The sympathetic nervous system in hypertension: differing effects of drug treatment. Eur Heart J 1998 Jun; 19 Suppl. F: 39–44
Mogensen CE. New treatment guidelines for a patient with diabetes and hypertension. J Hypertens Suppl 2003 Mar; 21 Suppl. 1: S25–30
Abellán J, Leal M, Hernández-Menárguez F, et al. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. Kidney Int Suppl 2005 Jan; 67 Suppl. 93: S20–4CrossRef
Frei M, Kuster L, Gardosch von Krosigk PP, et al. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994; 24 Suppl. 1: 25–8CrossRef
Prichard BNC, Küster LJ, Hughes PR, et al. Dose relation of blood pressure reduction with moxonidine: findings from three placebo- and active-controlled randomized studies. J Clin Basic Cardiol 2003; 6: 49–51
Camilleri G, Portal B, Quiniou G, et al. Comparison of the antihypertensive efficacy of and tolerance to two imidazoline receptor agonists: moxonidine and rilmenidine in monotherapy [in French]. Ann Cardiol Angeiol (Paris) 2001 Apr; 50(3): 169–74CrossRef
Prichard BNC, Simmons R, Rooks MJ, et al. A double-blind comparison of moxomidine and atenolol in the management of patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1992; 20 Suppl. 4: S45–9CrossRef
Wolf R. The treatment of hypertensive patients with at calcium antagonist or moxonidine: a comparison. J Cardiovasc Pharmacol 1992; 20 Suppl. 4: S42–4CrossRef
Feuring M, Cassel W, Thun B, et al. Moxonidine and ramipril in patients with hypertension and obstructive pulmonary disease. Clin Drug Invest 2000 Jul; 20: 19–24CrossRef
Trieb G, Jäger B, Hughes PR, et al. Long-term evaluation of the antihypertensive efficacy and tolerability of the orally acting imidazoline I1 receptor agonist moxonidine in patients with mild-to-moderate essential hypertension. Eur J Clin Res 1995; 7: 227–40
Rayner B, Coetzer E. Moxonidine is effective for controlling blood pressure in patients with resistant hypertension [abstract]. Cardiovasc J S Afr 2005 Mar; 16 (2 Suppl. 1): 20
Confirmation of the effectiveness and tolerability profile of the antihypertensive moxonidine: data from 14 post-marketing surveillance studies involving >91,000 patients. Hannover: Solvay Pharmaceuticals, 2005. (Data on file)
Peverill RE. Hypertension guidelines, meta-analyses and clinical trials: do we assume too much? Med J Aust 2005; 182(2): 82–
Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004; 22: 1543–8CrossRef
Kaaja RJ, Pöyhönen-Alho MK. Insulin resistance and sympathetic overactivity in women. J Hypertens 2005; 24: 131–41CrossRef
Pater C, Bhatnagar D, Berrou J-P, et al. A novel approach to treatment of hypertension in diabetic patients: a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of eprosartan versus ramipril with low-dose hydrochlorothiazide and moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2. Rationale and design [ISRCTN55725285]. Curr Control Trials Cardiovasc Med 2004 Oct 1; 5(1): 9PubMedCrossRef
Volume 66, Issue 4 , pp 477-496
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors